

Growth slump a concern; downgrade to REDUCE

Consumer Goods ▶ Result Update ▶ October 17, 2024

TARGET PRICE (Rs): 2,400

We downgrade Nestlé India to REDUCE from Add with a 14.3% cut in TP to Rs2,400 amid sustained topline pressures; our target valuation multiple reduces to 60x (~10% discount to last 5Y avg. fwd. P/E of 67x). Q2 result was weaker than street and our expectations, wherein sales growth was 1% (5% below expectations) and adjusted earnings declined 9% (14% below expectations). EBITDA margin saw 150bps YoY contraction amid surge in A&P spends; gross margin remained steady at 56%. Amid inflationary stress, Nestlé India's core categories saw demand pressure. Factoring in muted topline show in 1H, we lower revenue expectations by 3% over FY25-27. We cut our earnings 8% for FY25E and ~3% over FY26-27E. The recent stock correction has priced in near-term pressure, reflecting in 1Y fwd P/E at 62x near -1 SD (5Y avg).

Nestlé India: Financial Snapshot (Standalone)

Y/E Mar (Rs mn)	CY22	FY24	FY25E	FY26E	FY27E
Revenue	168,970	243,939	202,482	223,930	247,235
EBITDA	37,583	58,490	48,064	54,892	61,633
Adj. PAT	24,362	39,577	31,842	36,834	40,820
Adj. EPS (Rs)	25.3	32.8	33.0	38.2	42.3
EBITDA margin (%)	22.2	24.0	23.7	24.5	24.9
EBITDA growth (%)	5.3	24.5	2.7	14.2	12.3
Adj. EPS growth (%)	3.3	30.0	0.6	15.7	10.8
RoE (%)	107.2	109.2	82.3	84.6	96.4
RoIC (%)	67.5	88.6	86.2	85.9	107.7
P/E (x)	94.1	72.4	72.0	62.3	56.2
EV/EBITDA (x)	60.7	39.1	47.5	41.7	36.9
P/B (x)	93.3	85.8	52.2	53.1	55.2
FCFF yield (%)	0.9	2.7	1.1	1.4	2.6

Source: Company, Emkay Research

Demand slump concerning; Q2 revenue grew 1% with 1.5% decline in volume

Contrary to expectation of sequential performance improvement, Nestle India reported growth moderation to 1%, which implies volume decline of 1.5% in Q2FY25. Inflation pressure (in all major commodities – Milk, Cocoa, Coffee, and Palm oil) led to steady price hikes in the portfolio, which has started affecting sales growth. As per the management commentary, revenue pressure seems to be high for formula milk and instant noodles. New launches in the last eight years have sales contribution of 7%, it has eight innovation in the pipeline. The company has launched a new variant in noodles (Chatpata Besan) and will be launching Cerelac variants with no refined sugar (7 in Nov-24); among the 21 variants, 14 will be with no refined sugar. The company continues to leverage opportunity in the e-commerce channel (grew 38% YoY), where share of revenue expanded to 8.3% of domestic sales in Q2FY25 from 7.5% in Q1.

High A&P spends caused 150bps compression in EBITDA margin

Gross margin at 56.4%, expanded by 10bps YoY, but contracted by 110bps QoQ. Management noted inflationary stress from cocoa and coffee, and noted concern on elevated edible oil prices. Milk and packaging prices are likely to be stable ahead. We see any further inflation to be detrimental to its growth, given >20% cumulative price hikes in the last couple of years. EBITDA margin contracted by 150bps YoY, affected primarily by higher A&P spends in the business. EBITDA declined 5% YoY, while other income reduced 79% YoY amid lower liquidity, leading to earnings falling 8% YoY.

Recent correction factors near-term stress, valuation elevated on its strengths

Nestlé India's elevated valuations has been a factor of execution prowess, price power, strong parentage, and healthy return profile. We see that the recent correction is factoring in business pressures, its 1Y fwd P/E at 62x is at -1 SD 5Y historical average. We cut Sep-25E TP from Rs2,800 to Rs2,400, as we lower earnings by 3% and multiple to 60x (from 67x). We downgrade stock to REDUCE as we see the stock as fairly valued.


Target Price – 12M	Sep-25
Change in TP (%)	(14.3)
Current Reco.	REDUCE
Previous Reco.	ADD
Upside/(Downside) (%)	0.9
CMP (17-Oct-24) (Rs)	2,378.7

Stock Data	NEST
52-week High (Rs)	2,778
52-week Low (Rs)	2,310
Shares outstanding (mn)	964.2
Market-cap (Rs bn)	2,293
Market-cap (USD mn)	27,281
Net-debt, FY25E (Rs mn)	-8,998
ADTV-3M (mn shares)	1
ADTV-3M (Rs mn)	2,733.1
ADTV-3M (USD mn)	32.5
Free float (%)	37.2
Nifty-50	24,750
INR/USD	84.1
Shareholding, Jun-24	
Promoters (%)	62.8
FPIs/MFs (%)	11.9/9.2

Price Performance

(%)	1M	3M	12M
Absolute	(6.6)	(8.8)	2.0
Rel. to Nifty	(4.1)	(9.3)	(18.4)

1-Year share price trend (Rs)



Nitin Gupta

nitin.gupta@emkayglobal.com
+91 22 6612 1257

Pinky Mahato

pinky.mahato@emkayglobal.com
+91 22 6612 1306


Quarterly performance

Exhibit 1: Q2FY25 Quarterly performance

(Rs mn)	2QFY25	2QFY24	YoY (%)	1QFY25	QoQ (%)	2QFY25E	Var (%)
Total income	51,040	50,368	1.3	48,140	6.0	53,716	(5.0)
Cost of goods	22,139	21,916	1.0	20,388	8.6	22,964	(3.6)
Employee expenses	5,017	5,176	(3.1)	5,054	(0.7)	5,500	(8.8)
Other expenses	12,207	10,989	11.1	11,674	4.6	12,088	1.0
EBITDA	11,677	12,287	(5.0)	11,023	5.9	13,165	(11.3)
EBITDAM (%)	22.9	24.4	-150bps	22.9	0bps	24.5	-160bps
Depreciation	1,216	1,112	9.4	1,127	7.9	1,200	1.3
EBIT	10,461	11,176	(6.4)	9,896	5.7	11,965	(12.6)
EBITM (%)	20.5	22.2	-170bps	20.6	-10bps	22.3	-180bps
Interest cost	322	314	2.7	317	1.7	300	7.4
Other income	69	333	(79.4)	391	(82.5)	375	(81.7)
PBT	10,208	11,195	(8.8)	9,971	2.4	12,040	(15.2)
Tax	3,252	3,139	3.6	2,625	23.9	3,070	5.9
Tax rate (%)	31.9	28.0	380bps	26.3	550bps	25.5	640bps
Non-recurring items	2,908	1,026	183.5	120	2323.5	(150)	(2038.8)
PAT	9,864	9,081	9	7,466	32.1	8,820	11.8
Adj Profit	7,882	8,343	(5.5)	7,378	6.8	8,931	(11.7)
NPM (%)	15.4	16.6	-110bps	15.3	10bps	16.6	-120bps
EPS (Rs)	8.0	8.6	(7.7)	7.7	4.1	9.3	-14.0


Source: Company, Emkay Research

Exhibit 2: Nestlé revenue




Source: Company, Emkay Research


Exhibit 3: Nestlé revenue growth (YoY)




Source: Company, Emkay Research

Exhibit 4: Domestic revenue growth


Source: Company, Emkay Research

Exhibit 5: Domestic volume growth


Source: Company, Emkay Research

Exhibit 6: Nestlé EBITDA


Source: Company, Emkay Research

Exhibit 7: Nestlé EBITDA growth


Source: Company, Emkay Research

Exhibit 8: Adjusted PAT


Source: Company, Emkay Research

Exhibit 9: Adjusted PAT growth


Source: Company, Emkay Research

Exhibit 10: EBITDA margin


Source: Company, Emkay Research

Exhibit 11: Gross margin

Source: Company, Emkay Research

Exhibit 12: Staff costs


Source: Company, Emkay Research

Exhibit 13: Other expenses as a % of sales

Source: Company, Emkay Research

Valuations

Exhibit 14: Nestlé India's one-year forward P/E (on consensus)



Source: Bloomberg, Emkay Research

Exhibit 15: Key assumptions

	CY20	CY21	CY22	FY24E	FY25E	FY26E	FY27E
Income statement							
Total income growth	8.1%	10.1%	14.7%	15.7%	3.6%	10.6%	10.4%
Volume growth	2.6%	10.5%	5.6%	2.7%	-1.1%	7.3%	7.4%
Gross margin	57.5%	57.0%	54.1%	56.1%	56.8%	57.3%	57.3%
Royalty	4.9%	4.9%	4.9%	4.9%	4.9%	4.9%	4.9%
Advertisement	5.7%	5.2%	4.1%	5.3%	5.5%	5.5%	5.5%
EBITDA margin	24.1%	24.3%	22.2%	24.0%	23.7%	24.5%	24.9%
Tax rate	25.8%	23.9%	26.2%	25.5%	25.7%	25.5%	25.5%
Adj PAT growth	5.1%	12.5%	3.3%	30.0%	0.6%	15.7%	10.8%
EPS (Rs)	21.7	24.4	25.3	41.0	33.0	38.2	42.3
Balance Sheet							
ROE	106.1%	114.9%	107.2%	109.2%	82.3%	84.6%	96.4%
ROCE	140.9%	152.3%	145.6%	145.0%	110.7%	112.3%	129.3%
Inventory days (no. of)	39	39	42	39	32	32	32
Receivable days (no. of)	5	4	4	6	4	4	3
Payable days (no. of)	41	43	42	42	32	32	34

Source: Company, Emkay Research

Exhibit 16: Changes to our estimates

(Rs mn)	New estimates			Old estimates			Changes to estimate		
	FY25E	FY26E	FY27E	FY25E	FY26E	FY27E	FY25E	FY26E	FY27E
Net sales	201,280	222,659	245,903	207,689	229,832	253,616	-3%	-3%	-3%
Growth	3.8%	10.6%	10.4%	7.1%	10.7%	10.3%			
EBITDA	48,064	54,892	61,633	51,196	56,879	63,572	-6%	-3%	-3%
Growth	2.7%	14.2%	12.3%	9.4%	11.1%	11.8%			
EBITDA margin	23.9%	24.7%	25.1%	24.7%	24.7%	25.1%			
Adj PAT	31,842	36,834	40,820	34,712	38,030	41,936	-8%	-3%	-3%
Growth	0.6%	15.7%	10.8%	9.6%	9.6%	10.3%			
EPS (Rs)	33.0	38.2	42.3	36.0	39.4	43.6	-8%	-3%	-3%

Source: Emkay Research

Exhibit 17: Emkay estimates vs consensus estimates

(Rs mn)	Emkay estimates			Consensus estimates			Emkay vs Consensus estimates		
	FY25E	FY26E	FY27E	FY25E	FY26E	FY27E	FY25E	FY26E	FY27E
Revenue	201,280	222,659	245,903	211,807	235,550	257,163	-5%	-5%	-4%
Growth	3.8%	10.6%	10.4%	9.2%	11.2%	9.2%			
EBITDA	48,064	54,892	61,633	51,448	58,295	64,623	-7%	-6%	-5%
Growth	2.7%	14.2%	12.3%	10.0%	13.3%	10.9%			
EBITDA margin	23.7%	24.5%	24.9%	24.3%	24.7%	25.1%			
Adj PAT	31,842	36,834	40,820	34,366	39,294	44,111	-7%	-6%	-7%
Growth	0.6%	15.7%	10.8%	8.5%	14.3%	12.3%			
EPS (Rs)	33.0	38.2	42.3	35.7	40.5	45.5	-7%	-6%	-7%

Source: Bloomberg, Emkay Research

This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 10/18/2024 11:33 AM

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

Nestlé India: Standalone Financials and Valuations

Profit & Loss					
Y/E Mar (Rs mn)	CY22	FY24	FY25E	FY26E	FY27E
Revenue	168,970	243,939	202,482	223,930	247,235
Revenue growth (%)	14.9	15.5	3.8	10.6	10.4
EBITDA	37,583	58,490	48,064	54,892	61,633
EBITDA growth (%)	5.3	24.5	2.7	14.2	12.3
Depreciation & Amortization	4,030	5,378	4,920	5,641	6,484
EBIT	33,553	53,113	43,144	49,251	55,148
EBIT growth (%)	5.6	26.6	1.5	14.2	12.0
Other operating income	1,074	1,184	1,202	1,271	1,332
Other income	1,010	1,480	962	1,191	644
Financial expense	1,546	1,455	1,250	1,000	1,000
PBT	33,017	53,137	42,856	49,442	54,792
Extraordinary items	0	0	0	0	0
Taxes	8,655	13,560	11,014	12,608	13,972
Minority interest	0	0	0	0	0
Income from JV/Associates	0	0	0	0	0
Reported PAT	23,905	39,328	34,870	36,834	40,820
PAT growth (%)	11.5	31.6	10.8	5.6	10.8
Adjusted PAT	24,362	39,577	31,842	36,834	40,820
Diluted EPS (Rs)	25.3	32.8	33.0	38.2	42.3
Diluted EPS growth (%)	3.3	30.0	0.6	15.7	10.8
DPS (Rs)	19.6	16.0	21.8	31.2	25.3
Dividend payout (%)	79.1	49.0	60.2	81.7	59.6
EBITDA margin (%)	22.2	24.0	23.7	24.5	24.9
EBIT margin (%)	19.9	21.8	21.3	22.0	22.3
Effective tax rate (%)	26.2	25.5	25.7	25.5	25.5
NOPLAT (pre-IndAS)	24,758	39,559	32,056	36,692	41,085
Shares outstanding (mn)	964.2	964.2	964.2	964.2	964.2

Source: Company, Emkay Research

Cash flows					
Y/E Mar (Rs mn)	CY22	FY24	FY25E	FY26E	FY27E
PBT	33,017	53,137	42,856	49,442	54,792
Others (non-cash items)	327	277	0	0	0
Taxes paid	(8,412)	(12,988)	(11,014)	(12,608)	(13,972)
Change in NWC	(302)	(2,489)	(2,623)	1,042	21,033
Operating cash flow	27,374	41,748	37,455	43,326	68,693
Capital expenditure	(6,478)	18,870	(12,000)	(12,000)	(10,000)
Acquisition of business	0	0	0	0	0
Interest & dividend income	1,018	1,673	962	1,191	644
Investing cash flow	(4,046)	(12,374)	(10,638)	(10,809)	(11,956)
Equity raised/(repaid)	0	0	0	0	0
Debt raised/(repaid)	0	(1,000)	(11)	0	0
Payment of lease liabilities	0	0	0	0	0
Interest paid	(181)	(260)	(1,250)	(1,000)	(1,000)
Dividend paid (incl tax)	(20,980)	(30,082)	(24,346)	(37,604)	(42,425)
Others	(67)	300	0	0	0
Financing cash flow	(21,227)	(31,041)	(25,607)	(38,604)	(43,425)
Net chg in Cash	2,101	(1,667)	1,209	(6,087)	13,312
OCF	27,374	41,748	37,455	43,326	68,693
Adj. OCF (w/o NWC chg.)	27,676	44,237	39,944	42,284	47,661
FCFF	20,897	60,618	25,455	31,326	58,693
FCFE	20,369	60,836	25,167	31,517	58,337
OCF/EBITDA (%)	72.8	71.4	77.9	78.9	111.5
FCFE/PAT (%)	83.6	153.7	79.0	85.6	142.9
FCFF/NOPLAT (%)	84.4	153.2	79.4	85.4	142.9

Source: Company, Emkay Research

Balance Sheet					
Y/E Mar (Rs mn)	CY22	FY24	FY25E	FY26E	FY27E
Share capital	964	964	964	964	964
Reserves & Surplus	23,628	32,445	42,969	42,199	40,594
Net worth	24,592	33,409	43,933	43,163	41,559
Minority interests	0	0	0	0	0
Deferred tax liability (net)	(256)	0	0	0	0
Total debt	33,104	31,245	28,224	28,724	29,224
Total liabilities & equity	57,440	64,654	72,157	71,888	70,783
Net tangible fixed assets	30,437	34,603	39,708	46,623	51,673
Net intangible assets	0	0	0	0	0
Net ROU assets	0	0	0	0	0
Capital WIP	3,584	17,417	19,392	18,835	17,301
Goodwill	0	0	0	0	0
Investments [JV/Associates]	5,602	4,239	4,239	4,239	4,339
Cash & equivalents	11,629	8,188	8,998	2,911	18,723
Current assets (ex-cash)	38,280	40,783	37,722	40,768	25,832
Current Liab. & Prov.	32,091	40,576	37,902	41,489	47,086
NWC (ex-cash)	6,188	207	(179)	(721)	(21,254)
Total assets	57,440	64,654	72,157	71,888	70,783
Net debt	(11,629)	(8,188)	(8,998)	(2,911)	(18,723)
Capital employed	24,336	33,409	43,933	43,163	41,559
Invested capital	36,625	34,810	39,528	45,902	30,420
BVPS (Rs)	25.5	27.7	45.6	44.8	43.1
Net Debt/Equity (x)	(0.5)	(0.2)	(0.2)	(0.1)	(0.5)
Net Debt/EBITDA (x)	(0.3)	(0.1)	(0.2)	(0.1)	(0.3)
Interest coverage (x)	0.0	0.0	0.0	0.0	0.0
RoCE (%)	153.9	151.3	114.1	115.8	131.7

Source: Company, Emkay Research

Valuations and key Ratios					
Y/E Mar	CY22	FY24	FY25E	FY26E	FY27E
P/E (x)	94.1	72.4	72.0	62.3	56.2
P/CE(x)	80.8	63.8	62.4	54.0	48.5
P/B (x)	93.3	85.8	52.2	53.1	55.2
EV/Sales (x)	13.6	9.4	11.4	10.3	9.3
EV/EBITDA (x)	60.7	39.1	47.5	41.7	36.9
EV/EBIT(x)	68.0	53.8	53.0	46.5	41.2
EV/IC (x)	62.3	65.7	57.8	49.9	74.8
FCFF yield (%)	0.9	2.7	1.1	1.4	2.6
FCFE yield (%)	0.9	2.7	1.1	1.4	2.5
Dividend yield (%)	0.8	0.7	0.9	1.3	1.1
DuPont-RoE split					
Net profit margin (%)	14.4	16.2	15.7	16.4	16.5
Total asset turnover (x)	7.5	6.8	5.2	5.1	5.8
Assets/Equity (x)	1.0	1.0	1.0	1.0	1.0
RoE (%)	107.2	109.2	82.3	84.6	96.4
DuPont-RoIC					
NOPLAT margin (%)	14.7	16.2	15.8	16.4	16.6
IC turnover (x)	4.6	6.8	5.4	5.2	6.5
RoIC (%)	67.5	88.6	86.2	85.9	107.7
Operating metrics					
Core NWC days	(18.7)	(14.3)	(16.5)	(13.4)	(14.6)
Total NWC days	13.4	0.4	(0.3)	(1.2)	(31.4)
Fixed asset turnover	3.2	3.3	2.9	2.8	2.7
Opex-to-revenue (%)	31.9	32.1	33.1	32.8	32.4


Source: Company, Emkay Research

RECOMMENDATION HISTORY - DETAILS

Date	Closing Price (INR)	TP (INR)	Rating	Analyst
02-Oct-24	2,707	2,800	Add	Nitin Gupta
24-Sep-24	2,696	2,650	Add	Nitin Gupta
25-Jul-24	2,481	2,650	Add	Nitin Gupta
04-Jul-24	2,534	2,700	Add	Nitin Gupta
26-Jun-24	2,523	2,600	Add	Nitin Gupta
04-Jun-24	2,417	2,600	Add	Nitin Gupta
13-May-24	2,505	2,600	Reduce	Nitin Gupta
08-May-24	2,528	2,600	Reduce	Nitin Gupta
25-Apr-24	2,552	2,600	Reduce	Nitin Gupta
15-Apr-24	2,543	2,600	Reduce	Nitin Gupta
07-Apr-24	2,527	2,600	Reduce	Nitin Gupta
02-Apr-24	2,612	2,650	Reduce	Nitin Gupta

Source: Company, Emkay Research

RECOMMENDATION HISTORY - TREND



Source: Company, Bloomberg, Emkay Research

GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to be as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com.

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit www.emkayglobal.com to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company.

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

Disclaimer for U.S. persons only: Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

RESTRICTIONS ON DISTRIBUTION

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons¹ may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests² in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

¹ An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

² Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report:-

- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative's may have Financial Interest/proprietary positions in the securities recommended in this report as of October 17, 2024
- EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report
Disclosure of previous investment recommendation produced:
- EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's may have material conflict of interest in the securities recommended in this report as of October 17, 2024
- EGFSL, its affiliates and Research Analyst or his/her associate/relative's may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the October 17, 2024
- EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months.
- EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- EGFSL, its affiliates and/or and Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

Emkay Rating Distribution

Ratings	Expected Return within the next 12-18 months.
BUY	>15% upside
ADD	5-15% upside
REDUCE	5% upside to 15% downside
SELL	<15% downside

Emkay Global Financial Services Ltd.

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India
Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com

OTHER DISCLAIMERS AND DISCLOSURES:**Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) -:**

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company.

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. . Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit www.emkayglobal.com to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. EGFSL or its associates may have received compensation from the subject company in the past twelve months. Subject Company may have been client of EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates may have co-managed public offering of securities for the subject company in the past twelve months.